WO2009140215A3 - Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds - Google Patents

Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds Download PDF

Info

Publication number
WO2009140215A3
WO2009140215A3 PCT/US2009/043505 US2009043505W WO2009140215A3 WO 2009140215 A3 WO2009140215 A3 WO 2009140215A3 US 2009043505 W US2009043505 W US 2009043505W WO 2009140215 A3 WO2009140215 A3 WO 2009140215A3
Authority
WO
WIPO (PCT)
Prior art keywords
resistant
compounds
bacteria
strains
phanquinone
Prior art date
Application number
PCT/US2009/043505
Other languages
French (fr)
Other versions
WO2009140215A2 (en
Inventor
Michel E. Xilinas
Original Assignee
Geraghty, Erin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geraghty, Erin filed Critical Geraghty, Erin
Publication of WO2009140215A2 publication Critical patent/WO2009140215A2/en
Publication of WO2009140215A3 publication Critical patent/WO2009140215A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to new uses of known chelating compounds for the treatment of bacterial in fungal infections, particularly by methicilllin-resistant and other drug-resistant strains of bacteria and fungi. One of more chelating compound is administered with or without additional antibiotic or antifungal drugs to achieve improved therapy. Preferred chelating compounds include clioquinol, 5,7-dichloro-8-hydroxy-quinaldine, phanquinone, 5,7-dichloro-8-hydroxyquinoline, 5,7- di-iodo-8-hydroxyquinoline. By chelation of specific metal ions, these compounds treat any infection by bacteria or fungi whose pathogenicity depends upon metalloenzymes that require these cations. The compounds are also effective against infections caused by extended β lactamase and metallo β lactamase producing bacterial strains. Bacteria targeted by these methods include methicillin-resistant Staphylococcus aureus, penicillin resistant or intermediate resistant Streptococcus pneumoniae and other gram positive and multiresistant gram negative species and strains.
PCT/US2009/043505 2008-05-11 2009-05-11 Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds WO2009140215A2 (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US5221208P 2008-05-11 2008-05-11
US61/052,212 2008-05-11
US5304008P 2008-05-14 2008-05-14
US61/053,040 2008-05-14
US5603208P 2008-05-26 2008-05-26
US61/056,032 2008-05-26
US5607708P 2008-05-27 2008-05-27
US61/056,077 2008-05-27
US5711708P 2008-05-29 2008-05-29
US61/057,117 2008-05-29
US7877108P 2008-07-08 2008-07-08
US61/078,771 2008-07-08
US15691109P 2009-03-03 2009-03-03
US61/156,911 2009-03-03
US15946309P 2009-03-12 2009-03-12
US61/159,463 2009-03-12
US16894409P 2009-04-14 2009-04-14
US61/168,944 2009-04-14

Publications (2)

Publication Number Publication Date
WO2009140215A2 WO2009140215A2 (en) 2009-11-19
WO2009140215A3 true WO2009140215A3 (en) 2010-03-11

Family

ID=41319274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/043505 WO2009140215A2 (en) 2008-05-11 2009-05-11 Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds

Country Status (1)

Country Link
WO (1) WO2009140215A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847507A (en) * 2015-05-29 2018-03-27 德克抗生素股份公司 For treating the halo salicylanilide of fusobacterium infection

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940289B1 (en) * 2008-12-23 2014-09-12 Biopharmed AMINO HYDROXYQUINOLINE CLASS DERIVATIVES FOR THE TREATMENT OF PANCREATIC CANCER
GB0900786D0 (en) * 2009-01-19 2009-03-04 Natracine Uk Ltd Therapeutic compositions
NZ597050A (en) 2009-06-29 2014-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
IN2012DN01449A (en) * 2009-07-17 2015-06-05 Univ Denmark Tech Dtu
WO2011017519A2 (en) * 2009-08-05 2011-02-10 The Johns Hopkins University Inhibitors of methionine aminopeptidases and methods of treating disorders
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
CN101797251A (en) * 2010-01-21 2010-08-11 复旦大学 Inhibitor for acetylcoenzyme A synthetase in human pathogen clostridium difficile
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9150865B2 (en) 2010-11-09 2015-10-06 The University Of Chicago Role of ADAM10 and its relevance to disease and therapeutics
WO2012079582A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
AR084366A1 (en) 2010-12-20 2013-05-08 Incyte Corp N- (1- (REPLACED PHENYL) ETIL) -9H-PURIN-6-AMINAS AS PI3K INHIBITORS
KR101647545B1 (en) 2011-02-11 2016-08-10 모베르그 파르마 아베 Novel antifungal composition
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
DE102011106065A1 (en) * 2011-06-13 2012-12-13 Erlend Dinné Pharmaceutical preparation
BR122019020716B1 (en) 2011-09-02 2021-02-17 Incyte Holdings Corporation heterocyclylamines as pi3k inhibitors and pharmaceutical composition comprising them
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
US20150141415A1 (en) * 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
US20170304288A1 (en) * 2013-11-20 2017-10-26 Texas Southern University Formulations of Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
ES2970434T3 (en) 2014-09-12 2024-05-28 Union Therapeutics As Antibacterial use of halogenated salicylanilides
WO2016048304A1 (en) * 2014-09-24 2016-03-31 Colgate-Palmolive Company Bioavailability of metal ions
MD3262046T2 (en) 2015-02-27 2021-03-31 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
CA2984250A1 (en) * 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
TWI609013B (en) * 2015-05-07 2017-12-21 國立臺北科技大學 Novel compounds used for treating cancer
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
FR3038983A1 (en) * 2015-07-13 2017-01-20 Centre Nat De La Rech Scient (Cnrs) COMPOUNDS INHIBITING PSEUDOMONAS AERUGINOSA
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
CZ309768B6 (en) * 2017-06-05 2023-09-27 Pharmacy point s.r.o An antibacterial and antifungal hydrophilic gel composition based on a cross-linked copolymer of 2-hydroxyethyl methacrylate
WO2019060697A1 (en) 2017-09-22 2019-03-28 Becton, Dickinson And Company 4% trisodium citrate solution for use as a catheter lock solution
WO2019071325A1 (en) * 2017-10-13 2019-04-18 The University Of Queensland Zinc ionophores and uses thereof
CN107988097A (en) * 2017-11-29 2018-05-04 中国农业科学院油料作物研究所 The flavobacterium breve biocontrol bacterial strain of one high-efficiency degradation aflatoxin and its application
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN111808090B (en) * 2019-04-12 2023-05-02 中国医学科学院医药生物技术研究所 New Deril metal-beta-lactamase-1 inhibitor
WO2020242157A1 (en) * 2019-05-31 2020-12-03 건국대학교 글로컬산학협력단 Use of iox1 as antibiotic, anti-inflammatory, and anti-septic agent
US11806342B2 (en) * 2019-10-07 2023-11-07 Purdue Research Foundation Diiodohydroxyquinoline for the treatment of clostridium difficile infection
CN111233850B (en) * 2020-01-21 2022-09-23 南开大学 Naphthol derivative containing benzothiazole amino and heteroaryl and preparation method and application thereof
CN111514142B (en) * 2020-05-29 2021-04-06 江苏亚虹医药科技股份有限公司 Pharmaceutical composition containing nitroxoline prodrug and preparation method and application thereof
US11963955B2 (en) 2020-08-13 2024-04-23 Texas Southern University Compositions for and methods of inhibiting SARS-CoV2 infection
EP4304594A1 (en) * 2021-03-09 2024-01-17 Germanas, Juris Hydroxyquinoline compounds and methods of use as pigment modifying agents
US20220401432A1 (en) * 2021-05-27 2022-12-22 Yuk Yin Sham Therapeutic methods, combinations and kits
WO2023212291A1 (en) * 2022-04-29 2023-11-02 Virginia Tech Intellectual Properties, Inc. Treatment of pathogenic neisseria sp. infection with triazole antifungal agents
CN115650912A (en) * 2022-12-14 2023-01-31 灌南森迪门业有限公司 2-mercapto-6-methoxyquinoline-3-formaldehyde-N-oxide and synthesis method and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERGERON RJ ET AL.: "Bacteriostatic and fungostatic action of catecholamide iron chelators.", ANTIMICROB AGENTS CHEMOTHER., vol. 24, no. 5, November 1983 (1983-11-01), pages 725 - 730 *
CHEW BP ET AL.: "In vitro growth inhibition of mastitis causing bacteria by phenolics and metal chelators.", J DAIRY SCI., vol. 68, no. 11, November 1985 (1985-11-01), pages 3037 - 3046 *
METT H ET AL.: "Duodeno-pancreatic secretions enhance bactericidal activity of antimicrobial drugs.", ANTIMICROB AGENTS CHEMOTHER., vol. 26, no. 1, July 1984 (1984-07-01), pages 35 - 38 *
MURUGASU-OEI B ET AL.: "In vitro activity of the chelating agents nitroxoline and oxine against Mycobacterium bovis BCG.", INT J ANTIMICROB AGENTS., vol. 18, no. 6, December 2001 (2001-12-01), pages 579 - 582 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847507A (en) * 2015-05-29 2018-03-27 德克抗生素股份公司 For treating the halo salicylanilide of fusobacterium infection

Also Published As

Publication number Publication date
WO2009140215A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2009140215A3 (en) Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
Cascioferro et al. Therapeutic strategies to counteract antibiotic resistance in MRSA biofilm‐associated infections
NZ600134A (en) Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
WO2008041966A3 (en) Broad spectrum antibacterial compounds
WO2012034077A3 (en) Compositions and methods related to attenuated staphylococcal strains
BR0317564A (en) Compounds, compositions and methods for treating bacterial or fungal diseases
WO2015100331A3 (en) Phenazine derivatives as antimicrobial agents
TW201613575A (en) Treatment of polybacterial infections
WO2010115184A3 (en) Hydroxythienoquinolones and related compounds as anti-infective agents
MX2021002719A (en) Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains.
BRPI1010948A2 (en) COMPOSITION UNDERSTANDING AT LEAST TRANS-CINAMALDEHYDE AND THEIR RESPECTIVE USE IN THE TREATMENT OF BACTERIAL INFECTIONS, MORE PARTICULARLY IN THE TREATMENT OF NOSOCOMIAL DISEASES.
WO2007133712A3 (en) Antimicrobial therapy for bacterial infections
WO2018152436A8 (en) Phenazine derivatives as antimicrobial agents
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
WO2014179784A3 (en) Antimicrobial potentiators
WO2014165107A3 (en) Mannose derivatives for treating bacterial infections
EP4272831A3 (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2008036761A8 (en) Anti-microbial defensin-related peptides and methods of use
RU2015134149A (en) COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS
WO2013041663A3 (en) Modified apidaecin derivatives as antibiotic peptides
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
AU2012335397A8 (en) Novel bacteriophages
WO2010123599A3 (en) Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09747299

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09747299

Country of ref document: EP

Kind code of ref document: A2